Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024)
Raphael Pharmaceutical's (RAPH) quarterly Research & Development came in at $211000.0 in Q4 2024, up 160.63% year-on-year from $80957.0 in Q1 2024, and up 30.25% quarter-over-quarter from $162000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has disclosed Research & Development across 5 years of filings, most recently posting $211000.0 for Q4 2024.
- Research & Development for Q4 2024 came in at $211000.0, up 160.63% year-over-year; the trailing twelve-month figure through Dec 2024 was $776000.0 (up 36.38% YoY), and the FY2025 annual result was $631000.0, down 18.69% from the prior year.
- Research & Development came in at $211000.0 for Q4 2024 at Raphael Pharmaceutical, up from $162000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $676000.0 in Q4 2022 to a low of -$348000.0 in Q4 2023.
- The 5-year median for Research & Development is $190000.0 (2021), against an average of $199333.3.
- Peak annual rise in Research & Development reached 248.81% in 2023, while the deepest fall reached 151.48% in 2023.
- Raphael Pharmaceutical's Research & Development stood at $220000.0 in 2020, then climbed by 1.82% to $224000.0 in 2021, then surged by 201.79% to $676000.0 in 2022, then sank by 151.48% to -$348000.0 in 2023, then soared by 160.63% to $211000.0 in 2024.
- The last three Research & Development figures came in at $211000.0 (Q4 2024), $162000.0 (Q3 2024), and $24000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 222.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 180.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 138.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 934,363.43 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 296.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 97.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 103.35 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 46.94 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 39.38 Mn |
| 10 | Raphael Pharmaceutical | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 676,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 86,000.00 |
| Dec 31, 2021 | 224,000.00 |
| Sep 30, 2021 | 161,000.00 |
| Jun 30, 2021 | 222,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | 69,000.00 |